Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer

• Asıl Yazarlar: Jiangping Yang (Yazar), Jiaqi Han (Yazar), Yalan Zhang (Yazar), Muhelisa Muhetaer (Yazar), Nianyong Chen (Yazar), Xi Yan (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2022-09-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan (T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). Considering the exc...